Berkeley Compound Raises Energy Burn 18% in Mice Without Muscle Loss
A compound called TOFA raised energy expenditure by up to 18% in obese mice and spared lean muscle, Science Advances reports. It is untested in humans.

An experimental compound called TOFA raised the energy that obese mice burned by as much as 18%, and the animals lost fat without a significant drop in lean muscle, according to researchers at the University of California, Berkeley. The work appeared in the journal Science Advances. TOFA has not been tested in people.
The mice did not move more or run warmer to burn that extra energy. They also showed better blood sugar control, lower triglycerides (a type of blood fat) and improved signs of fatty liver disease.
How TOFA works in the body
The molecule is 5-tetradecyloxy-2-furoic acid, first discovered in the 1970s. It belongs to a group called ACC inhibitors, which block enzymes that build fatty acids. Other ACC inhibitors have reached mid-stage clinical trials, but none is approved for metabolic disease. Many of them raise blood triglycerides, which could raise heart risk.
The Berkeley team found that TOFA does a second job. It switches on two cellular receptors, PPARα and PPARδ, which control genes that let cells take up fatty acids and burn them for energy. Unlike other ACC inhibitors, TOFA did not raise triglycerides in the mice, possibly because of that second effect.
When the researchers gave mice two separate compounds, one blocking lipid production and one boosting energy expenditure, the pair worked less well than TOFA alone. The team reads this as a sign that one molecule doing several things at once matters.
Comparison with Ozempic and Wegovy
GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound mainly cut appetite and food intake. The article from Berkeley notes that they can cause nausea and digestive problems, and that reduced eating can raise the risk of muscle loss.
The team tested TOFA with semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) in mice. The combinations gave bigger improvements in body weight, blood glucose, insulin levels and triglycerides than either treatment alone. Senior author Anders Näär, a professor of metabolic biology and nutrition at Berkeley, said the group sees TOFA as “complementary rather than as a replacement” for GLP-1 drugs.
How sure is this?
All the results so far come from mice. Whether TOFA is safe or effective in humans has not been established, and the researchers say further studies are needed to learn whether the same effects occur in people and whether it would beat existing drugs in any way.
The paper is titled “A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders” (Science Advances, 2026, DOI 10.1126/sciadv.aed3119). The first author is Justin Y. Lee, now a postdoctoral researcher at UCSF, who did the work as a Berkeley Ph.D. student. Co-authors come from Berkeley, Massachusetts General Hospital, the University of California, San Diego, the Helmholtz Center Munich and ReRx Therapeutics.
Berkeley funded the research from discretionary resources, with added support from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core. The scientists have founded a biotechnology company, ReRx Therapeutics, to move the compound toward clinical use, backed by Nucleate and Berkeley SkyDeck.
Source: ScienceDaily
Site editor: Nikita Sheikin



